Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 2Completed 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Breast 4Dermatologic 3Sarcoma 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 467Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × glembatumumab vedotin × Breast × Clear all
NCT03473691 2024-12-09

Breast50

University of Virginia

Phase EARLY_PHASE1 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT01997333 2019-03-08

METRIC

Celldex Therapeutics

Phase 2 Completed
327 enrolled 17 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01156753 2017-07-02

EMERGE

Celldex Therapeutics

Phase 2 Completed
120 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡